BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/18/2026 9:51:23 AM | Browse: 0 | Download: 0
 |
Received |
|
2025-12-16 00:34 |
|
Peer-Review Started |
|
2025-12-16 00:35 |
|
First Decision by Editorial Office Director |
|
2026-01-06 09:41 |
|
Return for Revision |
|
2026-01-06 09:41 |
|
Revised |
|
2026-01-12 00:20 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-03-05 02:44 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-03-05 11:46 |
|
Articles in Press |
|
2026-03-05 11:46 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-06-10 06:13 |
|
Publish the Manuscript Online |
|
2026-06-18 09:51 |
| ISSN |
1949-8462 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Cardiac & Cardiovascular Systems |
| Manuscript Type |
Correspondence |
| Article Title |
Letter to the Editor: Beta-blockers vs calcium channel blockers in heart failure with preserved ejection fraction: An old question in need of new answers
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Rafael Vidal-Perez and Jose Manuel Vazquez-Rodriguez |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Rafael Vidal-Perez, Servicio de Cardiología, Unidad de Imagen y Función Cardíaca, Complexo Hospitalario Universitario A Coruña Centro de Investigación Biomédica en Red-Instituto de Salud Carlos III, As Xubias de Arriba-84, A Coruña 15006, Galicia, Spain. rafavidal@hotmail.com |
| Key Words |
Heart failure with preserved ejection fraction; Beta-blockers; Calcium channel blockers; Phenotype-guided therapy; Heart rate control |
| Core Tip |
Heart failure with preserved ejection fraction (HFpEF) remains a heterogeneous syndrome lacking robust disease-modifying therapies. This editorial critically examines the long-standing debate between beta-blockers and calcium channel blockers in HFpEF, integrating evidence from meta-analyses, observational studies, and a recent retrospective comparison. While beta-blockers may confer modest benefits in selected phenotypes - particularly in patients with atrial fibrillation or coronary artery disease - their potential to worsen chronotropic incompetence limits universal applicability. Calcium channel blockers appear largely safe and may reduce hospitalizations in specific settings. Overall, the analysis underscores the need for phenotype-driven, individualized treatment strategies and prospective trials to guide therapy in HFpEF. |
| Publish Date |
2026-06-18 09:51 |
| Citation |
Vidal-Perez R, Vazquez-Rodriguez JM. Letter to the Editor: Beta-blockers vs calcium channel blockers in heart failure with preserved ejection fraction: An old question in need of new answers. World J Cardiol 2026; 18(6): 117807
|
| URL |
https://www.wjgnet.com/1949-8462/full/v18/i6/117807.htm |
| DOI |
https://doi.org/10.4330/wjc.117807 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
